AnaptysBio
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, AnaptysBio sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
AnaptysBio: 7 sponsored US clinical trials, none currently recruiting.
AnaptysBio sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Rhinosinusitis, with 1 trials.
Upper-quartile sponsor footprint
AnaptysBio sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
NCT05935085
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
NCT03614923
Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT03533751
Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma
NCT03469934
Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
NCT02920021
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 7 |
Therapeutic Areas
How the AnaptysBio early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 4 completed (57%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Chronic Rhinosinusitis (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
AnaptysBio: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
AnaptysBio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this AnaptysBio page
7 registered trials is a research-attention snapshot, not an endorsement of AnaptysBio or any single study.
- None of AnaptysBio's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Chronic Rhinosinusitis is the condition AnaptysBio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Rhinosinusitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
AnaptysBio pipeline card: 7 registered trials from official public datasets.Report a data error.